Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
Authors O’Dell JR, Cohen SB, Thorne JC, Kremer J
Received 24 March 2018
Accepted for publication 23 April 2018
Published 3 July 2018 Volume 2018:10 Pages 97—101
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Chuan-Ju Liu
James R O’Dell,1 Stanley B Cohen,2 J Carter Thorne,3 Joel Kremer4
1Department of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA; 2Department of Internal Medicine, Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX, USA; 3Division of Rheumatology, University of Toronto, Southlake Regional Health Centre, Toronto, ON, Canada; 4The Center for Rheumatology, Albany Medical College, Albany, NY, USA
Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA.
Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort).
Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort).
Conclusion: MTX is underused in the treatment of RA in the USA.
Keywords: biologic, claims, methotrexate, tumor necrosis factor
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]